Company: ARWR
Filing Date: 2025-11-25
Form Type: 10-K
Source: 0000879407-25-000029
Chunk: 172

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-11-25
Form: 10-K
Item: Item 9B
Chunk 172
---
ITEM 9B.OTHER INFORMATION

(b) Trading Plans

During the fiscal quarter ended September 30, 2025, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):NameTitleAdoption or Termination DatePlan End DateShares Vesting and Subject to Sell-To-Cover (1)Other Shares Being Sold (Subject to Certain Conditions)Adeoye OlukotunBoard Member09/04/202512/24/2025n/a10,000Christopher AnzalonePresident and Chief Executive Officer09/19/202512/24/202650,000n/aDaniel ApelChief Financial Officer09/16/202504/30/202625,000n/aJames HamiltonChief Medical Officer, Head of R&D09/03/202501/16/202672,500n/aMauro FerrariBoard Member09/25/202512/31/2025n/a7,530Patrick O'BrienChief Operating Officer & General Counsel09/03/202501/07/202677,50020,000Victoria VakienerBoard Member09/03/202512/31/2025n/a10,040William WaddillBoard Member09/03/202512/31/2025n/a8,367(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.